Journal article

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

William G Wierda, Constantine S Tam, John N Allan, Tanya Siddiqi, Thomas J Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C Badoux, Bryone J Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M Pagel, Ian W Flinn, Cathy Zhou, Edith Szafer-Glusman, Joi Ninomoto, James P Dean, Danelle F James, Paolo Ghia

Blood | American Society of Hematology | Published : 2020


Background : Ibr is an established standard of care in CLL and is the only once-daily Bruton tyrosine kinase inhibitor with significant overall survival benefit in randomized phase 3 studies in first-line CLL (RESONATE-2; ECOG1912). The synergistic combination of Ibr + Ven (oral inhibitor of BCL2) has been shown to mobilize and clear CLL cells from multiple disease compartments leading to deep responses, providing a rationale to evaluate time-limited treatment (Jain et al. NEJM 2019). CAPTIVATE (PCYC-1142) is a multicenter phase 2 study (NCT02910583) of first-line Ibr + Ven with 2 cohorts: Minimal Residual Disease (MRD) and Fixed-Duration (FD). For both cohorts, patients (pts) received 3 cyc..

View full abstract

Citation metrics